nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Alzheimer's drug-development pipeline: 2016
|
Cummings, Jeffrey |
|
2016 |
2 |
4 |
p. 222-232 11 p. |
artikel |
2 |
A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol
|
Saito, Satoshi |
|
2016 |
2 |
4 |
p. 250-257 8 p. |
artikel |
3 |
Communication Bridge: A pilot feasibility study of Internet-based speech–language therapy for individuals with progressive aphasia
|
Rogalski, Emily J. |
|
2016 |
2 |
4 |
p. 213-221 9 p. |
artikel |
4 |
Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
|
Scheltens, Nienke M.E. |
|
2016 |
2 |
4 |
p. 233-240 8 p. |
artikel |
5 |
Measuring informed consent capacity in an Alzheimer's disease clinical trial
|
Guarino, Peter D. |
|
2016 |
2 |
4 |
p. 258-266 9 p. |
artikel |
6 |
Mnemonic strategy training of the elderly at risk for dementia enhances integration of information processing via cross-frequency coupling
|
Dimitriadis, Stavros I. |
|
2016 |
2 |
4 |
p. 241-249 9 p. |
artikel |
7 |
Multiple neuropathologies and dementia in the aging brain: A key role for cerebrovascular disease?
|
Charidimou, Andreas |
|
2016 |
2 |
4 |
p. 281-282 2 p. |
artikel |
8 |
SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy
|
Delay-Goyet, Philippe |
|
2016 |
2 |
4 |
p. 267-280 14 p. |
artikel |